APLM vs. DARE, JAGX, CALC, NXTC, NBRV, GANX, XLO, AADI, BOLT, and RMTI
Should you be buying Apollomics stock or one of its competitors? The main competitors of Apollomics include Daré Bioscience (DARE), Jaguar Health (JAGX), CalciMedica (CALC), NextCure (NXTC), Nabriva Therapeutics (NBRV), Gain Therapeutics (GANX), Xilio Therapeutics (XLO), Aadi Bioscience (AADI), Bolt Biotherapeutics (BOLT), and Rockwell Medical (RMTI). These companies are all part of the "pharmaceutical preparations" industry.
Daré Bioscience (NASDAQ:DARE) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, community ranking, valuation, earnings, dividends, analyst recommendations and risk.
Daré Bioscience has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Comparatively, Apollomics has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500.
6.7% of Daré Bioscience shares are held by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 5.3% of Daré Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Daré Bioscience's return on equity of 0.00% beat Apollomics' return on equity.
Daré Bioscience received 348 more outperform votes than Apollomics when rated by MarketBeat users. However, 75.00% of users gave Apollomics an outperform vote while only 73.13% of users gave Daré Bioscience an outperform vote.
Daré Bioscience has higher revenue and earnings than Apollomics.
In the previous week, Daré Bioscience had 3 more articles in the media than Apollomics. MarketBeat recorded 5 mentions for Daré Bioscience and 2 mentions for Apollomics. Apollomics' average media sentiment score of 0.21 beat Daré Bioscience's score of -0.50 indicating that Daré Bioscience is being referred to more favorably in the media.
Daré Bioscience presently has a consensus target price of $6.00, indicating a potential upside of 1,861.43%. Apollomics has a consensus target price of $5.00, indicating a potential upside of 1,011.11%. Given Apollomics' higher possible upside, research analysts clearly believe Daré Bioscience is more favorable than Apollomics.
Summary
Daré Bioscience and Apollomics tied by winning 7 of the 14 factors compared between the two stocks.
Get Apollomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APLM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apollomics Competitors List
Related Companies and Tools
